According to an international research team, people with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions. The research team was led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of iAnnals ...
View the Original article
According to research, the lot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75. The research as presented at the American College of Cardiology's 62nd Annual Scientific Session. Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing ...
